AinosAIMD
AIMD
About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Employees: 44
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1.75% less ownership
Funds ownership: 2.28% [Q3] → 0.54% (-1.75%) [Q4]
11% less funds holding
Funds holding: 9 [Q3] → 8 (-1) [Q4]
61% less capital invested
Capital invested by funds: $88.3K [Q3] → $34.5K (-$53.8K) [Q4]
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for AIMD.
Financial journalist opinion
Based on 3 articles about AIMD published over the past 30 days
Neutral
Accesswire
5 days ago
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study.
Neutral
Accesswire
1 week ago
Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025.
Neutral
Accesswire
3 weeks ago
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") and John Roy, managing director of WTR on Tuesday, April 8, 2025, at 10:00 a.m. ET. Ainos will provide insights into AI Nose applications, including its use in smart manufacturing and robots, as well as the impact of AI-driven digitized smell on industries beyond healthcare.
Neutral
Accesswire
1 month ago
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More
Another key win in expanding AI Nose's industrial opportunities Partnership to integrate AI Nose into ASE's factories and explore broader industrial use-cases SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 13, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting Ainos' strategic collaboration with Advanced Semiconductor Engineering, Inc. ("ASE"), the world's largest provider of semiconductor packaging and testing services. The partnership will integrate Ainos' AI Nose, an AI-powered electric nose technology, into ASE's factories, expanding AI Nose's opportunity in semiconductor manufacturing.
Neutral
Accesswire
1 month ago
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire / March 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, has announced a strategic collaboration with Advanced Semiconductor Engineering, Inc. (ASE), the world's largest provider of semiconductor packaging and testing services. This partnership aims to revolutionize semiconductor manufacturing by leveraging Ainos' patented AI Nose technology to analyze airborne chemicals into "Smell IDs", enhancing process efficiency, environmental safety, and environmental, social, and governance (ESG) compliance.
Neutral
Accesswire
1 month ago
Ainos Reports Full Year 2024 Financial Results
Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQAIMDW) ("Ainos", or the "Company") today announced its financial results for the fiscal year ended December 31, 2024. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "2024 marked another pivotal year as we transitioned from our COVID-19 antigen rapid test business to advancing the VELDONA® and pioneering AI Nose programs.
Neutral
Accesswire
1 month ago
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of smell digitization, today announced that Water Tower Research ("WTR") has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing.
Neutral
Accesswire
1 month ago
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security.
Neutral
Accesswire
2 months ago
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections.
Neutral
Accesswire
2 months ago
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.
Charts implemented using Lightweight Charts™